Newlyweds Raise Money for Dog's Cancer

A newlywed couple give up what they have to raise money for their loving dog:

"Angel's eyes say it all. She has been through hell: cancer, chemo and a bone marrow transplant.
But Angel is a smiling dog. She survived it all because of the tenacity of the two people who love her most and because of the unwavering support of her best friend, Romeo.

It began a little over a year ago, when Angel and Romeo's parents were planning their wedding and, almost simultaneously, found out Angel had B-cell lymphoma.
"The survival rate with chemo alone is 0 to 2 percent," said Kristie Sullens.

That was completely unacceptable to Johnny and Kristie Sullens. They begged their veterinarian for more options.
So the vet researched treatments around the country. Their one shot for a cure was a canine bone marrow transplant. The only place in the country now doing it in a clinical setting is at North Carolina State University. The cost is $16,000, and that would be after paying for six months of chemotherapy here at home."

Read More: http://www.wwltv.com/news/Couple-scrapes-together-16000-for-cancer-treat...

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap